A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
The request comes amid continuing uncertainty over federal funding, with research and thousands of jobs on the line.
The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...
Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...
Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the yearTessera to receive $150 ...
Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease. At ...
Q3 2025 Earnings Call Transcript November 24, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing ...
Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback